Long term treatment of the hyperkinetic heart syndrome with propranolol

M. Guazzi, A. Polese, F. Magrini, C. Fiorentini, M. T. Olivari

Research output: Contribution to journalArticlepeer-review


Twelve men suffering from the primary hyperkinetic heart syndrome (PHHS) displayed palpitation, rapid and forceful heart action, increased pulsations of the large arteries, cardiac systolic murmur, and the following circulatory values (averages): systolic arterial pressure (SAP) = 154 mm Hg; heart rate (HR) = 91 b/min; cardiac index (CI) = 5494 ml/min/m 2; left ventricular mean systolic ejection rate index (MSEJR) = 227 ml/min/m 2; left ventricular mean pre ejection ΔP/Δt = 1.32 mm Hg/msec. A two year followup during which propranolol was administered (80-160 mg/day) revealed good subjective improvement and disappearance of signs of circulatory hyperkinesis. At the end of this period the hemodynamic functions were as follows: SAP = 134; HR = 69; CI = 3489; MSEJR = 171; ΔP/Δt = 0.89. Substitution of placebo for the active drug caused prompt reappearance of symptoms of cardiac overactivity in each patient, and brought the circulatory functions back to these levels: SAP = 157; HR = 96; CI = 5530; MSEJR = 245; ΔP/Δt = 1.33. These findings lend further credence to the concept that the PHHS is, indeed, a definable disease entity; they also document that propranolol ameliorates the symptoms of the disease but is ineffective for the underlying disorder.

Original languageEnglish
Pages (from-to)465-474
Number of pages10
JournalAmerican Journal of the Medical Sciences
Issue number3
Publication statusPublished - 1975

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Long term treatment of the hyperkinetic heart syndrome with propranolol'. Together they form a unique fingerprint.

Cite this